Anticoagulant Fondaparinux Linked With Lower Risk of Bleeding, Death Following Heart Attack as Compared to Heparin
Treatment of non-ST-segment elevation myocardial infarction (NSTEMI) with anticoagulant fondaparinux had a lower risk of major bleeding events and death.